Hematologic Cancer Articles & Analysis: Older
19 news found
Groups listed by CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment ...
Groups listed by the CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer ...
” “Each year 300,000 Americans are diagnosed with breast cancer and metastatic breast cancer causes the vast majority of deaths from the disease: more than 43,000 annually. ...
A low percentage of patients received an antiemetic; 8.0% on elacestrant, 3.7% on fulvestrant, and 10.3% on AI, respectively. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia. Virginia Kaklamani, MD, DSc, breast medical oncologist and professor of medicine, UT Health San Antonio, MD Anderson ...
Ansell, MD, PhD, Professor of Medicine, Division of Hematology at the Mayo Clinic, with extensive expertise in B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas Todd A. ...
Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. ...
Other advancing programs include an oral brain penetrant inhibitor of PRMT5, JBI 778, and an oral brain penetrant PDL1 inhibitor, JBI 2174, for neurological cancers among others.” About JBI-802 JBI-802 is novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6. ...
LILRB4 is also expressed on certain hematologic cancer cells. Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for ...
Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers. Under the ...
Axumin (fluciclovine F18) presentations Category: Genitourinary Cancer Title: Detectability Rates and Impact on Management From High-Sensitivity Total- Body 18F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence Presenter: Soheila Fayeghi Azghadi, MD, Department of Radiation Oncology, Comprehensive Cancer ...
Daugherty is expanding his role with a very significant commitment to serve as medical monitor of our upcoming and future clinical trials as we seek to expand GP2’s potential to all HER2 positive breast cancer patients and to explore HER2 low breast cancer and other HER2 expressing cancers. ...
LAVA-051, LAVA’s lead product candidate, is a humanized bsTCE engineered to selectively target CD1d-expressing hematological cancers through activation of both gamma-delta T cells and type 1 natural killer T (NKT) cells. ...
B-cell lymphocytes are white blood cells circulating in the bloodstream: They play a critical role in our fight against infections and cancer. However, B-cell lymphocytes can become cancerous and transform into cancer cells, called lymphomas, which can ultimately lead to death. ...
ByAbologix
About JW Therapeutics Co-founded by Juno Therapeutics and Wuxi AppTec, JW Therapeutics is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. JW Therapeutics' vision is to ...
Utrecht, The Netherlands & Philadelphia – LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. ...
Alex Mayweg of Versant Ventures commented, “While CAR-T-based therapies have already demonstrated their power in the treatment of hematological cancers, their foray into solid tumors has proven to be less successful. ...
Thomas Matthes.The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.New therapeutics for the treatment of difficult to manage solid tumours will de developed by blocking the Olfml3 target. ...
ByAbologix
(NYSE: A) today launched two new products-the HaloPlexHS target enrichment system and ClearSeq Comprehensive Cancer research panel-designed to improve the speed and accuracy of clinical cancer research. ...
Agilent Technologies Inc., (NYSE: A) today introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in the same experiment. The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which now includes ...